This cooking tutorial provides step-by-step instructions on how to elevate three traditional BBQ side dishes—green beans, mashed potatoes, and macaroni and cheese—into restaurant-quality ...

Posts from this topic will be added to your daily email digest and your homepage feed. Despite the spec bump, the Xreal 1S are $50 cheaper than their predecessor. Despite the spec bump, the Xreal 1S ...

If you’re looking for a simple, sweet treat to gift friends or family this holiday season, homemade peanut brittle is an easy win. The recipe is so straightforward you may not even need a trip to the ...

XREAL is wrapping up 2025 with the launch of a new entry-level AR glasses model, the XREAL 1S. It sits below the more expensive XREAL One Pro (announced in July) in the lineup and is the first in the ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

A new analysis is one of the first to study whether spacing steps out or consolidating them was linked to better health outcomes. By Simar Bajaj A new study suggests that going on longer walks may ...

Dothée is a writer in Los Angeles. On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested ...

It's no secret that triple-A game development is becoming unsustainably expensive, so to support major titles, big studios should look to diversify the scale of their productions. That's according to ...

The explosive rise of GLP-1 medications—such as Mounjaro, Ozempic, and Wegovy—has ignited more than just headlines. It has fundamentally shifted how Americans access and pay for medications, driving ...

Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...

Eight percent of US adults older than 65 years have taken a GLP-1 agonist either to lose weight or to treat comorbidities like diabetes and cardiovascular disease. Older adults are drawn to the ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...